Gilead, Insitro to Collaborate on Nonalcoholic Steatohepatitis
April 16 2019 - 7:56AM
Dow Jones News
By Michael Dabaie
Gilead Sciences Inc. (GILD) said it will collaborate with
insitro to develop nonalcoholic steatohepatitis therapies.
Under the three-year agreement, insitro's platform will be used
to create disease models for NASH and discover targets that have an
influence on clinical progression and regression of the disease,
Gilead said Tuesday.
Gilead can advance up to five targets identified through this
collaboration and will be responsible for chemistry and
development.
Insitro will receive an upfront payment of $15 million, with
additional near-term payments up to $35 million based on
operational milestones. Insitro will be eligible to receive up to
$200 million for the achievement of milestones for each of the five
Gilead targets and up to low double-digit tiered royalties on net
sales.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
April 16, 2019 07:41 ET (11:41 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024